PITTSBURGH, April 25, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Letrozole Tablets USP, 2.5 mg, under a previously ...

Letrozole is prescribed for certain types of breast cancer. It's a generic medication and is available as the brand-name drug Femara. It comes as an oral tablet. The cost of letrozole can vary, but ...

PITTSBURGH Mylan on Monday announced that it has entered into a settlement agreement with Novartis Pharmaceuticals that will allow the generic manufacture to introduce a generic version of Novartis' ...

ZURICH (Reuters) - Novartis AG and Mylan Inc have agreed a deal over Mylan's copy-cat version of Novartis's Femara breast cancer drug, the companies said on Tuesday. Generic drugmaker Mylan said that ...

November 10, 2006 — The European Commission has approved lumiracoxib 100-mg tablets for once-daily dosing in the symptomatic relief of pain associated with knee and hip osteoarthritis (OA). Health ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Letrozole Tablets in the U.S., after the U.S.

The drug letrozole, which suppresses estrogen production, cut the risk of breast cancer recurrence nearly in half for older women who had already taken the standard tamoxifen treatment, researchers ...

The complete analysis of data from an international trial of the drug letrozole (Femara) confirms earlier reports that the drug reduced the recurrence of breast cancer in women previously treated with ...

WASHINGTON—A drug used to increase a woman's chances of becoming pregnant may cause birth defects and miscarriages, according to a safety alert issued Monday by Canadian health regulators. The drug ...

Switching to the drug letrozole following 5 years of treatment with tamoxifen reduces the risk of hormone-dependent breast cancer recurrence, but not overall survival, among postmenopausal women, ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)-- Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Letrozole Tablets in the U.S., after the U.S ...